Home » Consulting Services » Business and Data Analysis »

Business and Data Analysis

Business and Data Analysis

PHSI uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSI model and assess its impact on your financial results.

View our case studies related to business and data analysis:

340B Compliance Review

Accounting Firm Required Pharmacy Expertise

Client Selects Copay Reduction Program

Determining Competitive Market Landscape

Drug Resources Made Available via Manufacturer’s Website

Generic Competition Studied to Determine Effects on Brand Drug

Generic Market Forecasting

Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource

Manufacturer Seeks Pre-Launch Rebate Level Forecasting

Medicare PDP Develops Community Pharmacy MTM Program

PBM Contract Variance Analysis

PBM Positions Itself for Increased Rebate Yield

PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy

PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care

Proactive Response to Loss of Brand Patent Protection

Rebate Contracting Consolidation Process Directed by PHSI

Research Updates Brand Designation in Drug Databases

Specialty Drug Reimbursement by Pharmacy Type

U&C Pricing Strategy Critical for Chain Expansion

March 2019 Question of the Month

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%

February 2019 Question of the Month

What is the likelihood brand pharmaceutical manufacturers will slow drug price increases in 2019 based on the Trump administration’s proposals?

Highly Likely: 0%

Likely: 12.5%

Unlikely: 75%

Highly Unlikely: 12.5%

January 2019 Question of the Month

Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?

Yes: 57.1%

No: 42.9%

Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?

Yes: 85.7%

No: 14.3%